<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="brief-report" dtd-version="1.4"><!--The publisher of this article does not allow downloading of the full text in XML form.--><front><journal-meta><journal-id journal-id-type="nlm-ta">J Infect Dis</journal-id><journal-id journal-id-type="iso-abbrev">J Infect Dis</journal-id><journal-id journal-id-type="pmc-domain-id">1410</journal-id><journal-id journal-id-type="pmc-domain">jid</journal-id><journal-id journal-id-type="publisher-id">jid</journal-id><journal-title-group><journal-title>The Journal of Infectious Diseases</journal-title></journal-title-group><issn pub-type="ppub">0022-1899</issn><issn pub-type="epub">1537-6613</issn><publisher><publisher-name>Oxford University Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC10938212</article-id><article-id pub-id-type="pmcid-ver">PMC10938212.1</article-id><article-id pub-id-type="pmcaid">10938212</article-id><article-id pub-id-type="pmcaiid">10938212</article-id><article-id pub-id-type="pmid">37793170</article-id><article-id pub-id-type="doi">10.1093/infdis/jiad433</article-id><article-id pub-id-type="publisher-id">jiad433</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Brief Report</subject><subj-group subj-group-type="category-toc-heading"><subject>Hiv/Aids</subject></subj-group></subj-group><subj-group subj-group-type="category-taxonomy-collection"><subject>AcademicSubjects/MED00290</subject></subj-group></article-categories><title-group><article-title>Hepatitis C Treatment in People With HIV: Potential to Eliminate Disease and Disparity</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-2321-2295</contrib-id><name name-style="western"><surname>Falade-Nwulia</surname><given-names initials="O">Oluwaseun</given-names></name><aff>
<institution>Division of Infectious Diseases, Johns Hopkins University School of Medicine</institution>, <addr-line>Baltimore, Maryland</addr-line>, <country country="US">USA</country></aff><xref rid="jiad433-cor1" ref-type="corresp"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Lesko</surname><given-names initials="CR">Catherine R</given-names></name><aff>
<institution>Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health</institution>, <addr-line>Baltimore, Maryland</addr-line>, <country country="US">USA</country></aff></contrib><contrib contrib-type="author"><name name-style="western"><surname>Fojo</surname><given-names initials="AT">Anthony T</given-names></name><aff>
<institution>Division of General Internal Medicine, Johns Hopkins University School of Medicine</institution>, <addr-line>Baltimore, Maryland</addr-line>, <country country="US">USA</country></aff></contrib><contrib contrib-type="author"><name name-style="western"><surname>Keruly</surname><given-names initials="JC">Jeanne C</given-names></name><aff>
<institution>Division of Infectious Diseases, Johns Hopkins University School of Medicine</institution>, <addr-line>Baltimore, Maryland</addr-line>, <country country="US">USA</country></aff></contrib><contrib contrib-type="author"><name name-style="western"><surname>Moore</surname><given-names initials="RD">Richard D</given-names></name><aff>
<institution>Division of General Internal Medicine, Johns Hopkins University School of Medicine</institution>, <addr-line>Baltimore, Maryland</addr-line>, <country country="US">USA</country></aff></contrib><contrib contrib-type="author"><name name-style="western"><surname>Sutcliffe</surname><given-names initials="CG">Catherine G</given-names></name><aff>
<institution>Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health</institution>, <addr-line>Baltimore, Maryland</addr-line>, <country country="US">USA</country></aff></contrib><contrib contrib-type="author"><name name-style="western"><surname>Mehta</surname><given-names initials="SH">Shruti H</given-names></name><aff>
<institution>Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health</institution>, <addr-line>Baltimore, Maryland</addr-line>, <country country="US">USA</country></aff></contrib><contrib contrib-type="author"><name name-style="western"><surname>Chander</surname><given-names initials="G">Geetanjali</given-names></name><aff>
<institution>Division of General Internal Medicine, University of Washington</institution>, <addr-line>Seattle, Washington</addr-line>, <country country="US">USA</country></aff></contrib><contrib contrib-type="author"><name name-style="western"><surname>Thomas</surname><given-names initials="DL">David L</given-names></name><aff>
<institution>Division of Infectious Diseases, Johns Hopkins University School of Medicine</institution>, <addr-line>Baltimore, Maryland</addr-line>, <country country="US">USA</country></aff></contrib><contrib contrib-type="author"><name name-style="western"><surname>Sulkowski</surname><given-names initials="M">Mark</given-names></name><aff>
<institution>Division of Infectious Diseases, Johns Hopkins University School of Medicine</institution>, <addr-line>Baltimore, Maryland</addr-line>, <country country="US">USA</country></aff><xref rid="jiad433-FM10" ref-type="author-notes"/></contrib></contrib-group><author-notes><corresp id="jiad433-cor1">Correspondence: Oluwaseun Falade-Nwulia, MBBS, MPH, Division of Infectious Diseases, Johns Hopkins University School of Medicine, 5200 Eastern Ave, Mason F. Lord Center Tower Suite 381, Baltimore, MD 21224 (<email>ofalade1@jhmi.edu</email>).</corresp><fn id="jiad433-FM10" fn-type="COI-statement"><p>
<bold>
<italic toggle="yes">Potential conflicts of interest</italic>.</bold> M. S. reports research funds paid to his institution by Janssen, Vir, and GSK (HBV); and consulting fees from AbbVie, Antios, Assembly Bio, Atea, GSK, Gilead, Precision Bio, and Vir. O. F. N. reports research funds paid to her institution by Abbvie, Inc; and consulting fees from Gilead. D. T. reports consulting fees from Merck, Excision Bio, and Evrys Bio. S. H. M. reports materials support from Abbott Diagnostics. All other authors report no potential conflicts.</p><p>All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.</p></fn></author-notes><pub-date pub-type="collection"><day>15</day><month>3</month><year>2024</year></pub-date><pub-date pub-type="epub" iso-8601-date="2023-10-05"><day>05</day><month>10</month><year>2023</year></pub-date><volume>229</volume><issue>3</issue><issue-id pub-id-type="pmc-issue-id">457867</issue-id><fpage>775</fpage><lpage>779</lpage><history><date date-type="received"><day>21</day><month>5</month><year>2023</year></date><date date-type="editorial-decision"><day>25</day><month>9</month><year>2023</year></date><date date-type="accepted"><day>02</day><month>10</month><year>2023</year></date><date date-type="corrected-typeset"><day>20</day><month>10</month><year>2023</year></date></history><pub-history><event event-type="pmc-release"><date><day>05</day><month>10</month><year>2024</year></date></event><event event-type="pmc-live"><date><day>05</day><month>10</month><year>2024</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2024-10-05 00:25:16.960"><day>05</day><month>10</month><year>2024</year></date></event></pub-history><permissions><copyright-statement>&#169; The Author(s) 2023. Published by Oxford University Press on behalf of Infectious Diseases Society of America. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com</copyright-statement><copyright-year>2023</copyright-year><license><ali:license_ref>https://academic.oup.com/pages/standard-publication-reuse-rights</ali:license_ref><license-p>This article is published and distributed under the terms of the Oxford University Press, Standard Journals Publication Model (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://academic.oup.com/pages/standard-publication-reuse-rights">https://academic.oup.com/pages/standard-publication-reuse-rights</ext-link>)</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="jiad433.pdf"/><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="jiad433.pdf"/><abstract><title>Abstract</title><p>Access to direct acting antivirals (DAAs) may be associated with reductions in hepatitis C virus (HCV) viremia prevalence among people with human immunodeficiency virus (PWH). Among 3755 PWH, estimated HCV viremia prevalence decreased by 94.0% from 36% (95% confidence interval [CI], 27%&#8211;46%) in 2009 (pre-DAA era) to 2% (95% CI, 0%&#8211;4%) in 2021 (DAA era). Male sex, black race, and older age were associated with HCV viremia in 2009 but not in 2021. Injection drug use remained associated with HCV viremia in 2009 and 2021. Targeted interventions are needed to meet the HCV care needs of PWH who use drugs.</p></abstract><abstract abstract-type="teaser"><p>Among 3755 people with HIV, availability of direct acting antivirals (DAA) was associated with a reduction in HCV viremia prevalence from 36% in 2009 (pre-DAA era) to 2% in 2021 (DAA era) and changes in characteristics associated with HCV viremia.</p></abstract><kwd-group><kwd>hepatitis C</kwd><kwd>elimination</kwd><kwd>HIV</kwd><kwd>health equity</kwd></kwd-group><funding-group><award-group award-type="grant"><funding-source><institution-wrap><institution>National Institutes of Health</institution><institution-id institution-id-type="DOI">10.13039/100000002</institution-id></institution-wrap></funding-source><award-id>K01 AA028193</award-id><award-id>U01 DA036935</award-id><award-id>K24DA034621</award-id><award-id>K08MH118094</award-id><award-id>R01MD018539</award-id><award-id>K24 AA027483</award-id></award-group></funding-group><counts><page-count count="5"/></counts><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front></article></pmc-articleset>